Clinical Trials

We are developing a robust clinical trial program to test the efficacy and safety of our investigative medicines.

Study	Trial Overview
Program: JANX007 (PSMA x CD3 TRACTr) Status: Active, Recruiting	The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449.

Study

Trial Overview

Program:

JANX007 (PSMA x CD3 TRACTr)

Status:

Active, Recruiting

The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC.

For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449.

We have a range of precision immuno-oncology programs in development designed to address large numbers of patients in desperate need.

See our pipeline